The use of recombinant human erythropoietin in lung transplantation.
Recombinant human erythropoietin (r-HuEPO) was administered in 4 lung transplant recipients to treat chronic anemia beyond the immediate postoperative period. There were 2 males and 2 females with a mean age of 38 years (range 22-49). None of the patients had major infection or rejection problems, and no blood products were used. Because of different individual responses duration of therapy was 1 to 17 weeks (median 5) with a total dosage ranging from 8 to 36 x 10(3) IU (mean 21 x 10(3)). The median single dose was 58 IU/kg (range 36-100). Hemoglobin levels increased significantly from 9.1 +/- 0.2 to 12.7 +/- 0.3 g/dl (mean +/- SE; p < 0.01). There were no side effects. r-HuEPO is recommended in treatment of chronic anemia in lung transplant patients to save blood products and to exclude the potential risk of transfusion-transmitted viral infections.
End
A
A
Abteilung für Herz-Thoraxchirurgie, Universitätsklinik für Chirurgie, Wien.
Stift
A
A
Ringl
H
H
Inhauser
T
T
Grimm
M
M
Geissler
K
K
Stockenhuber
F
F
Klepetko
W
W
D000328:Adult; D000740:Anemia / Q000097:blood / Q000139:chemically induced / Q000628:therapy*; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects; D001803:Blood Transfusion; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006452:Hemoglobinometry; D006801:Humans; D016040:Lung Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000097:blood / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; D004921:Erythropoietin; D001379:Azathioprine